Payment overview · 2025
General Payments
$1,130.15
40 reported records · 13 companies
Healthcare provider profile · identity verified
Ravinder Singh, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · RANCHO CUCAMONGA, CA · NPI 1447289962
Verified facts
What the public records show
CMS Open Payments records show Ravinder Singh, M.D. received $1,130.15 in general payments during 2025 across 40 reported records.
Abbott Laboratories accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $387.10 | 34.2% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $123.24 | 10.9% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $108.91 | 9.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $95.81 | 8.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $83.54 | 7.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $77.86 | 6.9% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $69.95 | 6.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.29 | 3.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $31.73 | 2.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.30 | 2.8% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $31.23 | 2.8% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $22.97 | 2.0% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.22 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,130.15 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $387.10 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $85.58 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $84.77 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $83.54 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $77.86 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $77.86 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $77.66 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $69.95 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.27 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $52.64 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.47 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $31.73 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $31.30 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.28 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $31.23 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 113 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 53 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 42 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
109 | 37 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
113 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 953 | 287 |
| Levothyroxine Sodium | Levothyroxine Sodium | 651 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 545 | 161 |
| Losartan Potassium | Losartan Potassium | 488 | 159 |
| Metformin Hcl | Metformin Hcl | 468 | 147 |
| Omeprazole | Omeprazole | 418 | 132 |
| Zolpidem Tartrate | Zolpidem Tartrate | 418 | 73 |
| Tramadol Hcl | Tramadol Hcl | 415 | 117 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 407 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 312 | 94 |
| Lorazepam | Lorazepam | 273 | 80 |
| Alprazolam | Alprazolam | 242 | 74 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 239 | 66 |
| Lisinopril | Lisinopril | 228 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 225 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 224 | 66 |
| Gabapentin | Gabapentin | 218 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 214 | 63 |
| Simvastatin | Simvastatin | 207 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 206 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 202 | 72 |
| Trazodone Hcl | Trazodone Hcl | 197 | 54 |
| Sertraline Hcl | Sertraline Hcl | 195 | 56 |
| Atenolol | Atenolol | 190 | 57 |
| Carvedilol | Carvedilol | 189 | 38 |
| Furosemide | Furosemide | 164 | 63 |
| Alendronate Sodium | Alendronate Sodium | 145 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 49 |
| Temazepam | Temazepam | 144 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 41 |
| Finasteride | Finasteride | 131 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 31 |
| Eliquis | Apixaban | 113 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 41 |
| Famotidine | Famotidine | 110 | 33 |
| Synthroid | Levothyroxine Sodium | 109 | 37 |
| Ozempic | Semaglutide | 108 | 28 |
| Ibuprofen | Ibuprofen | 107 | 39 |
| Allopurinol | Allopurinol | 103 | 32 |
| Pregabalin | Pregabalin | 102 | 24 |
| Lovastatin | Lovastatin | 99 | 31 |
| Azithromycin | Azithromycin | 98 | 88 |
| Xarelto | Rivaroxaban | 91 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 21 |
| Donepezil Hcl | Donepezil Hcl | 88 | suppressed |
| Glimepiride | Glimepiride | 80 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 22 |
| Potassium Chloride | Potassium Chloride | 78 | 33 |
| Montelukast Sodium | Montelukast Sodium | 76 | 21 |
| Jardiance | Empagliflozin | 74 | 22 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 74 | 20 |
| Clonazepam | Clonazepam | 72 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 51 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 15 |
| Baclofen | Baclofen | 67 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 13 |
| Irbesartan | Irbesartan | 56 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 55 | 11 |
| Farxiga | Dapagliflozin Propanediol | 53 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 18 |
| Meloxicam | Meloxicam | 53 | 19 |
| Valsartan | Valsartan | 53 | 17 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 52 | 12 |
| Metformin Hcl Er | Metformin Hcl | 50 | 15 |
| Spironolactone | Spironolactone | 48 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 46 | 11 |
| Myrbetriq | Mirabegron | 45 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 44 | 21 |
| Benazepril Hcl | Benazepril Hcl | 44 | 14 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 43 | suppressed |
| Linzess | Linaclotide | 42 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 17 |
| Naproxen | Naproxen | 41 | 12 |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 39 | suppressed |
| Trulicity | Dulaglutide | 39 | 13 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 39 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Invokana | Canagliflozin | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 33 |
| Celecoxib | Celecoxib | 37 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 27 |
| Memantine Hcl | Memantine Hcl | 36 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 11 |
| Glipizide Er | Glipizide | 35 | suppressed |
| Prednisone | Prednisone | 35 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 29 |
| Diazepam | Diazepam | 34 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 11 |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 29 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 34 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 33 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Fentanyl | Fentanyl | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 18 |
| Azelastine Hcl | Azelastine Hcl | 29 | 11 |
| Bupropion Xl | Bupropion Hcl | 29 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Progesterone | Progesterone, Micronized | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | 13 |
| Prolia | Denosumab | 28 | 19 |
| Tradjenta | Linagliptin | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Estradiol | Estradiol | 25 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | 13 |
| Glipizide | Glipizide | 22 | 11 |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 12 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 12 |
| Methylprednisolone | Methylprednisolone | 20 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 11 |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Nucynta Er | Tapentadol Hcl | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Nystatin | Nystatin | 15 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Klor-Con 8 | Potassium Chloride | 12 | suppressed |
| Lyllana | Estradiol | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Yuvafem | Estradiol | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,130.15 · 40 records | Abbott Laboratories | AIRSUPRA, CREON, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, Radicava, TONMYA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, XIFAXAN, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error